Amplifications, mutations, and overexpression of EGFR family members have been described in epithelial ovarian cancer, and pre-clinical data have suggested that interfering with the signalling activity of these pathways in ovarian cancer cells can result in antitumour activity. This evidence concerns the gene EGFR and ovarian carcinoma.